Abstract: There is provided an ophthalmic pharmaceutical preparation comprising menthyl ester of indomethacin as an active ingredient. Also provided are different possible formulations of the ophthalmic preparation, and different methods of treating ophthalmic irritation using the ophthalmic preparation.
Abstract: The invention relates to a sustained release pharmaceutical composition, containing mebicar, for the treatment of anxiety, depression and other psychiatric and neurological disorders.
Abstract: The invention describes the use of an injectable form of Idebenone to induce protect from neuronal damage, improve recovery after brain trauma; stroke, intoxication, neurodegenerative diseases, memory loss or neuropathology associated with neuroinflammation or infection damage and to restore cognitive function, suppress disorientation, alcoholic and drug abuse associated syndromes and other signs of neuronal damage.
Abstract: The invention describes use of injectable form of Idebenone to improve recovery after general anesthesia and of cognitive functions, suppress disorientation and other signs of neuronal damage.
Abstract: Colloidal compositions, loaded with non-covalently bonded antibiotics, can be efficiently used for the treatment of severe bacterial pneumonia and other serious lung infections such as tuberculosis. Such formulations, comprised of biodegradable nanoparticles or nanocapsules with incorporated antibiotics, show a significant increase in antibacterial activity, extended and sustained drug release and a decrease in frequency of the drug administration. Antibiotics of various types, such as aminoglycosides, glycopeptides and others can be successfully incorporated into a nanoparticulate colloidal delivery system.
Type:
Application
Filed:
December 31, 2007
Publication date:
July 2, 2009
Applicant:
AlphaRx Inc.
Inventors:
Joseph Schwarz, Michael Weisspapir, Hai Yan Gao
Abstract: The stabilization of benzoyl peroxide for extended periods of time is disclosed. The stabilized solution contains from between 0.5% and 20% organic peroxide and a stabilizer for preventing degradation of said peroxide in the solution.
Abstract: The stabilization of benzoyl peroxide for extended periods of time is disclosed. The stabilized solution contains from between 0.5% and 20% organic peroxide and a stabilizer for preventing degradation of said peroxide in the solution.
Abstract: A topical composition for treatment of skin disorders such as acne is disclosed. The composition includes benzoyl peroxide in an amount from between 0.5 and 20% by weight. There is also provided a water miscible solvent for solubilizing the benzoyl peroxide in an amount from between 10% and 95% by weight and finally, a water miscible or water dispersible surfactant is present in an amount from between 0.5 and 95% by weight.
Abstract: A vehicle for topical application which contains a liquid eutectic mixture of hydrophobic compounds to improve solubility of pharmaceutically active component and enhance topical and transdermal delivery.
Abstract: A delivery method and product for enhancing the bioavailability of an active ingredient by prolonged relatively constant release. The method involves mixing with subsequent granulation and compression of a mixture to result in a solid core tablet. The composition includes a biologically active material matrixed or otherwise contained within a hydrophobic phase with the latter absorbed onto a sorbent. The sorbent and hydrophobic phase are in a ratio of between 1:10 and 10:1. The mixture further includes a pharmaceutically acceptable surfactant. The composition, once tableted into a solid core provides spontaneous release of the biologically active material over a predetermined time frame for substantially constant bioavailability.
Abstract: A delivery method and product for enhancing the bioavailability of an active ingredient by prolonged relatively constant release. The method involves mixing with subsequent granulation and compression of a mixture to result in a solid core tablet. The composition includes a biologically active material matrixed or otherwise contained within a hydrophobic phase with the latter absorbed onto a sorbent. The sorbent and hydrophobic phase are in a ratio of between 1:10 and 10:1. The mixture further includes a pharmaceutically acceptable surfactant. The composition, once tableted into a solid core provides spontaneous release of the biologically active material over a predetermined time frame for substantially constant bioavailability.
Abstract: Toothpaste incorporating chlorhexidine bigluconate for improved adhesive onto the surface of the teeth. A second embodiment discusses the use of triclosan and in combination with sodium monofluorphosphate for use in the toothpaste.